BMY Factor-Based Stock Analysis

Validea's guru fundamental report indicates that Bristol-Myers Squibb (BMY) receives an 88% rating based on their P/B Growth Investor model, which is based on the strategy of Partha Mohanram. The model favors low book-to-market stocks with sustained future growth characteristics, and BMY passes most of the model's tests, except for the research and development to assets criterion. Mohanram's research focuses on identifying growth stocks that maintain their upward trajectory, contrasting with academic research that often finds value investing more effective.

Analysis

Bristol-Myers Squibb (BMY), a large-cap growth stock within the Biotechnology & Drugs industry, has scored an 88% rating according to Validea's P/B Growth Investor model, based on Partha Mohanram's strategy. This model identifies low book-to-market stocks with characteristics suggesting sustained future growth, and a score above 80% indicates notable interest. BMY satisfies most of the model's fundamental criteria, including Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, the relationship between Cash Flow and ROA, ROA Variance, Sales Variance, Advertising to Assets, and Capital Expenditures to Assets. The primary area where BMY did not meet the model's criteria is 'Research and Development to Assets'. The overall positive evaluation, reflected in a BMY-specific sentiment score of 0.8, suggests that, according to this specific academic-originated growth model, BMY exhibits many traits of a growth stock likely to maintain its upward trajectory, despite the R&D expenditure relative to assets not meeting the model's threshold.

Key Decisions for Investors

• Investors utilizing growth-oriented quantitative strategies, particularly those mirroring Partha Mohanram's P/B Growth model, should consider BMY for further investigation due to its high 88% rating and strong performance across multiple fundamental growth metrics.
• It is crucial to conduct further due diligence on BMY's 'Research and Development to Assets' ratio, as this specific metric's failure could have implications for long-term innovation and growth, especially pertinent within the Biotechnology & Drugs sector.
• Given the model's aim to distinguish sustainable growth stocks, BMY may appeal to investors seeking fundamentally vetted growth opportunities, but they should weigh the significance of the R&D expenditure profile against the otherwise positive indicators from this specific investment framework.